Matignon Launches Major New European Device Fund
This article was originally published in Start Up
Executive Summary
Europe has a remarkable tradition of clinical thought leaders who develop major new medical device technologies. Yet European device company start-up activity lags far behind the rate of clinical breakthroughs. There are several reasons for this, including the dearth of European venture capital willing to back these start-ups. Matignon Technologies sees this gap in financing of European device start-ups as an opportunity, and has just launched one of the largest European funds dedicated primarily to medical technology.
You may also be interested in...
The Lure of Late-Stage Device Investing
In 2006, the number of late-stage private equity deals in the medical device sector is up significantly from 2005. At the IN3 East medtech conference in October, a lively panel of venture capital investors from Galen Partners, 3i, Matignon Technologies and OrbiMed Advisors discussed why this is so, and the risks, benefits and models for late-stage investing.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.